Clinical trials evaluating pictilisib (GDC-0941) have not advanced; however, other pan and isoform specific PI3K inhibitors, such as copanlisib (BAY80–6946), duvelisib (IPI-145), and idelalisib (CAL-101) have been approved by the FDA for the treatment of relapsed and refractory follicular lymphoma (37, 38, 39). The gene discussed is PIK3CA; the disease is follicular lymphoma.